Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States

Documents similaires

• Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
  par: Kaleb Tesfai, et autres
  Publié: (2026)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  par: Kaleb Tesfai, et autres
  Publié: (2025)
• Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
  par: Pojsakorn Danpanichkul, et autres
  Publié: (2025)
• Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
  par: Kelly Torosian, et autres
  Publié: (2024)
• Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
  par: Lana Bridi, et autres
  Publié: (2024)